WEIHAI SHIDAI MARINE BIOTECHNOLOGY CO., LTD.

shidaimarine.com

As Asia's most professional manufacturer of liquid seaweed fertilizer, SHIDAI MARINE has been - engaged in an agriculture research program for 6 years - focused on kelp business and industry for more than 20 years - equipped with professional enzymolysis equipment over 300 sets - cultivating on a Laminaria Japonica farming base covering 1,000 hectares With all these experience, technology and resources, SHIDAI MARINE thus developed a process to extract essential nutrients from fresh kelp cells, while ultimately preserving their bioactivity beneficial to plant growth and development. And LJ KELP is therefore created accordingly. Numerous research programs have proved that LJ KELP plays a positive and effective role, especially in promoting root growth, flowering and fruits initiation and stress resistance.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

news image

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

news image

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

Cell and Gene Therapy

BIOCENTRIQ® AND KYTOPEN® EXPAND PARTNERSHIP TO EXPEDITE IMPACT OF TRANSFORMATIVE GENE-EDITING TECHNOLOGY ON CELL THERAPY MANUFACTURING

PRNewswire | June 12, 2023

news image

BioCentriq®, a strategic CDMO specializing in cell therapy announced that it has expanded its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). The partnership was originally announced in March of 2021. In the initial phase of the collaboration, the Kytopen and BioCentriq teams worked together to test transfection of T-cells using Kytopen's Flowfect® technology and the potential impact to both autologous and ...

Read More

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

news image

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More
news image

Medical

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More
news image

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

news image

Cell and Gene Therapy

BIOCENTRIQ® AND KYTOPEN® EXPAND PARTNERSHIP TO EXPEDITE IMPACT OF TRANSFORMATIVE GENE-EDITING TECHNOLOGY ON CELL THERAPY MANUFACTURING

PRNewswire | June 12, 2023

BioCentriq®, a strategic CDMO specializing in cell therapy announced that it has expanded its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). The partnership was originally announced in March of 2021. In the initial phase of the collaboration, the Kytopen and BioCentriq teams worked together to test transfection of T-cells using Kytopen's Flowfect® technology and the potential impact to both autologous and ...

Read More
news image

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us